Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan

OBJECTIVES: Real-world evidence on the safety and effectiveness of direct-acting antivirals in patients infected with chronic hepatitis C virus (HCV) genotypes (GTs) 3, 4, 5, or 6 in Japan is limited. This prospective observational study assesses the real-world safety profile and treatment effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Mita, Eiji, Liu, Lauren J., Shing, Danielle, Force, Lindsey, Aoki, Kouji, Nakamoto, Daisuke, Ishizaki, Akinobu, Konishi, Hiroki, Mizutani, Hajime, Ng, Leslie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258100/
https://www.ncbi.nlm.nih.gov/pubmed/36047126
http://dx.doi.org/10.2169/internalmedicine.0067-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258100/
https://www.ncbi.nlm.nih.gov/pubmed/36047126
http://dx.doi.org/10.2169/internalmedicine.0067-22

Ejemplares similares